American Century Companies’s Viking Therapeutics VKTX Stock Holding History

American Century Companies’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$67.6M	Buy	2,078,577 +1,773,211	+581%	+$57M	0.03%	612
2025 Q4	$10.7M	Buy	305,366 +9,173	+3%	+$325K	0.01%	1416
2025 Q3	$7.78M	Sell	296,193 -2,791	-0.9%	-$83.3K	﹤0.01%	1531
2025 Q2	$7.92M	Buy	298,984 +1,255	+0.4%	+$33K	﹤0.01%	1465
2025 Q1	$7.19M	Sell	297,729 -3,853	-1%	-$122K	﹤0.01%	1444
2024 Q4	$12.1M	Buy	301,582 +25,824	+9%	+$1.47M	0.01%	1263
2024 Q3	$17.5M	Buy	275,758 +2,309	+0.8%	+$135K	0.01%	1081
2024 Q2	$14.5M	Sell	273,449 -558,683	-67%	-$36.6M	0.01%	1091
2024 Q1	$68.2M	Sell	832,132 -1,391,690	-63%	-$61.9M	0.04%	446
2023 Q4	$41.4M	Buy	2,223,822 +21,594	+1%	+$282K	0.03%	567
2023 Q3	$24.4M	Buy	2,202,228 +822,156	+60%	+$11.8M	0.02%	733
2023 Q2	$22.4M	Buy	1,380,072 +1,355,183	+5,445%	+$28.4M	0.02%	724
2023 Q1	$431K	Buy	24,889 +5,544	+29%	+$57.3K	﹤0.01%	2180
2022 Q4	$182K	Buy	+19,345	New	+$86.4K	﹤0.01%	2354
2020 Q1	–	Sell	-574,424	Closed	-$4.61M	–	1729
2019 Q4	$4.61M	Buy	574,424 +260,768	+83%	+$1.9M	﹤0.01%	815
2019 Q3	$2.16M	Buy	313,656 +18,918	+6%	+$141K	﹤0.01%	960
2019 Q2	$2.45M	Buy	294,738 +57,272	+24%	+$489K	﹤0.01%	995
2019 Q1	$2.36M	Sell	237,466 -10,750	-4%	-$90K	﹤0.01%	970
2018 Q4	$1.9M	Sell	248,216 -5,753	-2%	-$68.8K	﹤0.01%	981
2018 Q3	$4.42M	Buy	+253,969	New	+$3.02M	﹤0.01%	883

Other funds holding VKTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

American Century Companies's VKTX Position: Q1 2026 in Review

American Century Companies increased its Viking Therapeutics (VKTX) stake by 581% in Q1 2026, buying an estimated $57M and bringing the position to 2,078,577 shares worth $67.6M. The position accounts for 0.03% of the portfolio, ranked #612.

American Century Companies first reported a position in VKTX in Q3 2018 and has held it in 20 quarters since. The position peaked at $68.2M in Q1 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

American Century Companies held 2,078,577 shares of Viking Therapeutics worth $67.6M as of Q1 2026.
American Century Companies bought 1,773,211 Viking Therapeutics shares in Q1 2026, an estimated $57M.
Viking Therapeutics made up 0.03% of American Century Companies's portfolio in Q1 2026, its #612 holding.
American Century Companies first reported a position in Viking Therapeutics in Q3 2018 and has held it in 20 quarters since.
American Century Companies's Viking Therapeutics position peaked at $68.2M in Q1 2024.
410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on American Century Companies's 13F filing for Q1 2026, filed 15 May 2026.